Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax-based regimens

被引：1

作者：

Serafin, Andrea ^{[1
]}

Cellini, Alessandro ^{[1
]}

Cavarretta, Chiara Adele ^{[1
]}

Ruocco, Valeria ^{[1
]}

Angotzi, Francesco ^{[1
]}

Zatta, Ivan ^{[1
]}

Frezzato, Federica ^{[1
]}

Bonaldi, Laura ^{[2
]}

Martines, Annalisa ^{[2
]}

Pravato, Stefano ^{[1
]}

Piazza, Francesco ^{[1
]}

Trentin, Livio ^{[1
]}

Visentin, Andrea ^{[1
]}

机构：

[1] Univ Padua, Dept Med, Hematol Unit, Via Nicolo Giustiniani 2, I-35128 Padua, PD, Italy

[2] Veneto Inst Oncol, Immunol & Mol Oncol Unit, IOV IRCCS, Padua, Italy

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 205卷 / 01期

关键词：

CK; high CK; MRD; venetoclax; CLL;

D O I：

10.1111/bjh.19517

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Although the unfavourable prognostic role of complex karyotype (CK) in chronic lymphocytic leukaemia (CLL) patients treated with chemoimmunotherapy has been clarified, its impact on the outcome of patients being treated with novel targeted agents, and especially with venetoclax-based regimens, remains to be resolved. In fact, only few studies, utilizing data derived from clinical trials (e.g. MURANO, CLL14, GAIA-CLL13), specifically focus on this topic while real-word evidence is missing. In our real-life retrospective study conducted on 61 patients with CLL and treated with venetoclax-based regimens in any therapeutic line, we documented a remarkable lower progression-free survival in patients harbouring both CK and high CK, while overall response rate (including complete remissions and partial remissions) and overall survival are not affected by CK in our population.

引用

页码：189 / 193

页数：5

共 50 条

[1] Clinical outcomes in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax-based regimens
Hampel, Paul
Rabe, Kari
Wang, Yucai
Kenderian, Saad
Ding, Wei
Muchtar, Eli
Leis, Jose
Koehler, Amber
Tsang, Mazie
Parrondo, Ricardo
Bubik, Rachel
Schwager, Susan
Hanson, Curtis
Braggio, Esteban
Slager, Susan
Shi, Min
Van Dyke, Daniel
Call, Timothy
Kay, Neil
Parikh, Sameer
LEUKEMIA & LYMPHOMA, 2023, 64 : S183 - S185
[2] Clinical Outcomes with Venetoclax-Based Treatment Regimens in Patients with Chronic Lymphocytic Leukemia (CLL)
Hampel, Paul J.
Rabe, Kari G.
Wang, Yucai
Kenderian, Saad S.
Ding, Wei
Muchtar, Eli
Leis, Jose F.
Koehler, Amber
Tsang, Mazie
Parrondo, Ricardo
Bubik, Rachel
Schwager, Susan Marie
Hanson, Curtis A.
Braggio, Esteban
Slager, Susan L.
Shi, Min
Van Dyke, Daniel L.
Call, Timothy G.
Kay, Neil E.
Parikh, Sameer A.
BLOOD, 2023, 142
[3] Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
Thompson, Meghan C.
Harrup, Rosemary A.
Coombs, Catherine C.
Roeker, Lindsey E.
Pu, Jeffrey J.
Choi, Michael Y.
Barr, Paul M.
Allan, John N.
Simkovic, Martin
Leslie, Lori
Rhodes, Joanna
Chong, Elise A.
Kamdar, Manali
Skarbnik, Alan
Lansigan, Frederick
McCall, Brittany
Saja, Khalid
Dyer, Martin J. S.
Walter, Harriet S.
Lefebure, Marcus
Thadani-Mulero, Maria
Boyer, Michelle
Biondo, Juliana
Sail, Kavita
Manzoor, Beenish S.
Furman, Richard
Bantilan, Kurt S.
Goy, Andre
Feldman, Tatyana
Labella, Dominic
Schuster, Stephen J.
Park, Jae
Palomba, Lia
Zelenetz, Andrew
Eyre, Toby A.
Kater, Arnon P.
Seymour, John F.
Mato, Anthony R.
BLOOD ADVANCES, 2022, 6 (15) : 4553 - 4557
[4] COMPLEX KARYOTYPE AS A PROGNOSTIC MARKER IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS DURING TREATMENT WITH CHEMOIMMUNOTHERAPY BTKI AND VENETOCLAX
Tocci, D.
Peccia, K.
Crupi, R.
Ciofini, S.
Bocchia, M.
Gozzetti, A.
HAEMATOLOGICA, 2024, 109 : 95 - 95
[5] Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib
Mauro, Francesca R.
Foa, Robin
LANCET ONCOLOGY, 2018, 19 (01): : 7 - 8
[6] Pneumonia in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens: A Real-World Analysis of the Polish Adult Leukemia Group (PALG)
Kalicinska, Elzbieta
Jablonowska-Babij, Paula
Morawska, Marta
Iskierka-Jazdzewska, Elzbieta
Drozd-Sokolowska, Joanna
Paszkiewicz-Kozik, Ewa
Szukalski, Lukasz
Strzala, Judyta
Gosik, Urszula
Debski, Jakub
Andrasiak, Iga
Skotny, Anna
Jamroziak, Krzysztof
Wrobel, Tomasz
CANCERS, 2024, 16 (24)
[7] Pneumonia in patients with chronic lymphocytic leukemia treated with venetoclax-based regimens: A real-world analysis of Polish Adult Leukemia Group (PALG)
Kalicinska, Elzbieta
Jablonowska-Babij, Paula
Morawska, Marta
Iskierka-Jazdzewska, Elzbieta
Drozd-Sokolowska, Joanna
Paszkiewicz-Kozik, Ewa
Szukalski, Lukasz
Strzala, Judyta
Gosik, Urszula
Debski, Jakub
Andrasiak, Iga
Skotny, Anna
Jamroziak, Krzysztof
Wrobel, Tomasz
EJHAEM, 2025, 6 (01):
[8] REAL-WORLD EFFECTIVENESS AND TREATMENT PATTERNS OF VENETOCLAX-BASED REGIMENS AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN COMMUNITY SETTINGS
Zakeri, M.
Emechebe, N.
Chowdhery, R.
Jawaid, D.
Alhasani, H.
Manzoor, B. S.
VALUE IN HEALTH, 2023, 26 (06) : S54 - S55
[9] Real-World Efficacy of Venetoclax-Based Regimens in Patients with Chronic Lymphocytic Leukemia in Israel: A Multicenter Prospective Study
Herishanu, Yair
Goldschmidt, Neta
Itchaki, Gilad
Levi, Itai
Aviv, Ariel
Fineman, Riva
Dally, Najib
Tadmor, Tamar
Ruchlemer, Rosa
Abadi, Uri
Shvidel, Lev
Braester, Andrei
Cohen, Raanan
Frankel, Neta
Ofek, Keren
Berelovich, Jenia
Grunspan, Moshe
Benjamini, Ohad
BLOOD, 2021, 138 : 3727 - +
[10] The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype
Strati, Paolo
Wang, Feng
Tambaro, Francesco P.
Thompson, Philip A.
Burger, Jan A.
Jain, Nitin
Ferrajoli, Alessandra
Bose, Prithviraj
Estrov, Zeev
Keating, Michael J.
Futreal, Andrew
Takahashi, Koichi
Wierda, William G.
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 187 (01) : E1 - E4

← 1 2 3 4 5 →